Blood markers in methamphetamine psychosis
Part of Mental health clinical trials.
This study looks at two blood proteins (LRFN5 and OLFM4) in people with methamphetamine use disorder or methamphetamine-induced psychosis, compared to healthy controls. Results may help understand the biology of these conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 64 years old
- You cannot have taken any psychiatric medications in the past month
- You must be diagnosed with either methamphetamine use disorder or methamphetamine-induced psychosis (or be a healthy control without any psychiatric condition)
- You cannot have high blood pressure, diabetes, kidney disease, arthritis, lupus, heart disease, severe brain disorders, or immune system illnesses
- You cannot have alcohol use disorder or (for healthy controls) any drug use
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the electrical activity of the heart (ECG) in people who use methamphetamine, including those who develop psychosis from it. It compares them to healthy volunteers to see if methamphetamine affects heart function.
This study looks for patterns in psychiatric symptoms among people who have psychotic symptoms caused by methamphetamine use. You may qualify if you are 18-65, haven't taken psychiatric medication for at least a month, and do not have certain other health conditions.
This study compares people who have psychosis from methamphetamine and also use cannabis with those who only have methamphetamine-induced psychosis. It aims to understand how cannabis may affect their symptoms.
This study uses brain scans to see how men with methamphetamine use disorder react to images or reminders of the drug. It aims to understand cravings and brain activity, which could help improve treatments.
This study observes patients with psychosis to help tell if it is caused by schizophrenia or by methamphetamine use, so doctors can offer the right treatment.
This study tests a support program for people with heart failure who also use methamphetamine and want to quit. It aims to improve both heart health and recovery from substance use.
Hear when a new Methamphetamine Use Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.